DK1203761T3 - Calciumreceptoraktive forbindelser - Google Patents

Calciumreceptoraktive forbindelser

Info

Publication number
DK1203761T3
DK1203761T3 DK01204920T DK01204920T DK1203761T3 DK 1203761 T3 DK1203761 T3 DK 1203761T3 DK 01204920 T DK01204920 T DK 01204920T DK 01204920 T DK01204920 T DK 01204920T DK 1203761 T3 DK1203761 T3 DK 1203761T3
Authority
DK
Denmark
Prior art keywords
phenyl
substits
substd
opt
naphthyl
Prior art date
Application number
DK01204920T
Other languages
Danish (da)
English (en)
Inventor
Scott T Moe
Wagenen Bradford C Van
Manuel F Balandrin
Eric G Delmar
Edward F Nemeth
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23390556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1203761(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/353,784 external-priority patent/US6011068A/en
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of DK1203761T3 publication Critical patent/DK1203761T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DK01204920T 1994-12-08 1995-10-23 Calciumreceptoraktive forbindelser DK1203761T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/353,784 US6011068A (en) 1991-08-23 1994-12-08 Calcium receptor-active molecules
PCT/US1995/013704 WO1996012697A2 (fr) 1994-10-21 1995-10-23 Composes capables de moduler l'activite du recepteur de calcium

Publications (1)

Publication Number Publication Date
DK1203761T3 true DK1203761T3 (da) 2005-04-11

Family

ID=23390556

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01204920T DK1203761T3 (da) 1994-12-08 1995-10-23 Calciumreceptoraktive forbindelser

Country Status (25)

Country Link
US (1) US6211244B1 (fr)
EP (4) EP1203761B1 (fr)
JP (3) JP2882882B2 (fr)
KR (2) KR100293621B1 (fr)
CN (2) CN1312116C (fr)
AT (2) ATE359259T1 (fr)
AU (1) AU709303B2 (fr)
BR (1) BRPI9509411B8 (fr)
CA (1) CA2202879C (fr)
CZ (2) CZ290670B6 (fr)
DE (4) DE122005000033I1 (fr)
DK (1) DK1203761T3 (fr)
ES (2) ES2285707T3 (fr)
FR (1) FR05C0029I2 (fr)
HK (2) HK1046900B (fr)
HU (2) HU228150B1 (fr)
LU (1) LU91182I2 (fr)
NL (1) NL300199I2 (fr)
NZ (1) NZ297157A (fr)
PL (1) PL183499B1 (fr)
PT (1) PT1203761E (fr)
RU (1) RU2195446C2 (fr)
TW (2) TW200402407A (fr)
UA (1) UA55374C2 (fr)
WO (1) WO1996012697A2 (fr)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
EP1203761B1 (fr) * 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Composés capables de moduler l'activité du récepteur de calcium
JPH10507934A (ja) * 1995-07-26 1998-08-04 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 代謝指向型グルタミン酸受容体に活性を示す化合物を同定するためのキメラ受容体および方法、ならびに神経学的障害および疾患の治療におけるそのような化合物の使用
EP1770083B1 (fr) * 1996-05-01 2009-04-29 Nps Pharmaceuticals, Inc. Composés servant a déclencher l'activité d'un recepteur d'ions inorganiques
DK0907631T3 (da) * 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
EP1258471B1 (fr) * 1996-05-01 2007-01-24 Nps Pharmaceuticals, Inc. Composés servant à déclencher l'activité d'un récepteur d'ions anorganiques
TW510896B (en) 1996-07-08 2002-11-21 Kirin Brewery Calcium receptor active compounds, the salt or hydrate thereof, and pharmaceutical composition comprising the same
US6210964B1 (en) * 1997-08-18 2001-04-03 The Brigham And Women's Hospital, Inc. Avian extracellular calcium-sensing receptor
US6172091B1 (en) 1998-10-14 2001-01-09 Ortho-Mcneil Pharmaceutical, Inc. 1,2-Disubstituted cyclopropanes
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
DE60036758T2 (de) * 1999-08-04 2008-07-24 Sumitomo Chemical Co., Ltd. Verfahren zur Herstellung von optisch aktiver 3,3,3-Trifluor-2-hydroxy-2-methylpropionsäure und deren Salze
JP4595178B2 (ja) * 1999-08-04 2010-12-08 住友化学株式会社 アミン化合物、中間体、製造法および光学分割剤
US6797842B2 (en) * 2000-05-11 2004-09-28 Central Glass Company, Limited Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6849761B2 (en) 2002-09-05 2005-02-01 Wyeth Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
WO2004069793A2 (fr) * 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Nouveaux amines cycliques substitues en position 2 comme modulateurs du recepteur de detection de calcium
US7205322B2 (en) * 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) * 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
FR2855754B1 (fr) * 2003-06-05 2005-07-08 Oreal Compsition, notamment cosmetique, comprenant une amine carbonylee
ES2401769T5 (es) 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
HUE028373T2 (en) 2004-05-28 2017-02-28 Mitsubishi Tanabe Pharma Corp Arylalkylamines and processes for their preparation
US20050288377A1 (en) * 2004-06-14 2005-12-29 Cantor Thomas L Use of calcimimetic as an adynamic bone disease related treatment
CN1989097A (zh) * 2004-07-22 2007-06-27 帝斯曼知识产权资产管理有限公司 用于制备非对映异构体富集的化合物的方法
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
MX2007011153A (es) * 2005-03-17 2007-12-12 Amgen Inc Metodos para reducir la calcificacion.
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
US7250533B2 (en) * 2005-05-16 2007-07-31 Teva Pharmaceutical Industries Ltd Process for preparing Cinacalcet hydrochloride
WO2006127932A2 (fr) * 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Purification de cinacalcet
CA2605764A1 (fr) * 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Hydrochlorure de cinacalcet amorphe et sa preparation
AU2006285080B2 (en) * 2005-09-02 2012-05-03 Amgen Inc. Methods of modulating intestinal fluid balance
US7595161B2 (en) 2005-11-10 2009-09-29 Hansjoerg Martin Rothe Efficacy of calcimimetic agents
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
EP1965805B1 (fr) * 2005-11-25 2009-12-02 Galapagos SAS Dérivés de l'urée utiles comme modulateurs des récepteurs du calcium
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
CA2882048C (fr) 2006-02-03 2020-03-24 Opko Renal, Llc Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
US8415501B2 (en) 2006-03-23 2013-04-09 Amgen, Inc. Methods and compositions for making and using polymorphs of cinacalcet
AU2007240317B2 (en) 2006-04-20 2012-11-29 Amgen Inc. Stable emulsion formulations
US7393967B2 (en) * 2006-04-27 2008-07-01 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
JP5027214B2 (ja) * 2006-04-27 2012-09-19 テバ ファーマシューティカル インダストリーズ リミティド シナカルセット塩基の調製法
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
WO2008000422A1 (fr) * 2006-06-27 2008-01-03 Sandoz Ag Forme amorphe de cinacalcet
EP1914224A1 (fr) * 2006-10-19 2008-04-23 Sandoz AG Chlohydrate de cinacalcete amorphe
US20090197970A1 (en) * 2006-06-27 2009-08-06 Sandoz Ag Crystalline form of cinacalcet
GB0613674D0 (en) 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
MX2009002335A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones solidas de un compuesto activo receptor de calcio.
CA2663436A1 (fr) * 2006-10-04 2008-04-10 Pfizer Products Inc. Derives de pyrido[4,3-d]pyrimidin-4(3h)-one utilises en tant qu'antagonistes du recepteur calcique
CA2672956C (fr) * 2006-10-26 2015-02-10 Amgen Inc. Agents modulant le recepteur sensible au calcium
WO2008058236A2 (fr) * 2006-11-08 2008-05-15 Dr. Reddy's Labortories, Ltd. Procédés de préparation d'hydrochlorure de cinacalcet
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
US20080255181A1 (en) * 2006-12-15 2008-10-16 University Of Heidelberg Methods for treating podocyte-related disorders
EP2139462B1 (fr) 2007-03-30 2014-01-22 Amgen Inc. Composés calcimimétiques pour leur utilisation dans le traitement des troubles intestinaux
WO2008122010A1 (fr) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Substances calcimimétiques pharmaceutiques
WO2009047644A2 (fr) 2007-04-25 2009-04-16 Cytochroma Inc. Procédé de traitement d'une insuffisance et d'une carence en vitamine d
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
EP2156846B1 (fr) * 2007-05-08 2014-08-13 Ajinomoto Co., Inc. Agent prophylactique ou thérapeutique contre la diarrhée
EP2170805B1 (fr) 2007-06-21 2016-03-16 Amgen Inc. Procédés de synthèse du cinacalcet et de ses sels
ITMI20071261A1 (it) 2007-06-22 2008-12-23 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet
US8324396B2 (en) * 2007-07-10 2012-12-04 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2009025792A2 (fr) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Formes cristallines de cinacalcet fumarate et de cinacalcet succinate et leurs procédés de préparation
WO2009065406A2 (fr) * 2007-11-23 2009-05-28 Leo Pharma A/S Nouveaux composés hydrocarbonés cycliques pour le traitement de maladies
CN101959530A (zh) 2008-02-25 2011-01-26 味之素株式会社 糖尿病或肥胖症的预防或治疗剂
WO2009107579A1 (fr) * 2008-02-25 2009-09-03 味の素株式会社 Agent pour communiquer un goût corporel
WO2009119554A1 (fr) 2008-03-24 2009-10-01 味の素株式会社 Promoteur pour la sécrétion de bicarbonate dans le tractus gastro-intestinal
CA2719256A1 (fr) * 2008-03-28 2009-10-01 Amgen Inc. Procedes de traitement de lesions epitheliales
WO2009128523A1 (fr) 2008-04-17 2009-10-22 味の素株式会社 Agent immunostimulant
EP2321256B1 (fr) * 2008-06-18 2014-11-12 ERREGIERRE S.p.A. Procédé pour la synthèse de chlorhydrate de cinacalcet
WO2010015935A2 (fr) * 2008-08-06 2010-02-11 Actavis Group Ptc Ehf Sels de cinacalcet insaturé et procédés de préparation du chlorhydrate de cinacalcet
JP5551597B2 (ja) * 2008-08-22 2014-07-16 第一三共株式会社 シクロアルキルアミン誘導体
WO2010043721A1 (fr) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Inhibiteurs d’oxydases et leur utilisation
US20110318417A1 (en) * 2008-12-08 2011-12-29 Actavis Group Ptc Ehf Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010086129A1 (fr) 2009-01-27 2010-08-05 Rathiopharm Gmbh Complexe d'inclusion comprenant du cinacalcet et de la cyclodextrine
EP2398763A2 (fr) 2009-02-19 2011-12-28 ZaCh System S.p.A. Procédé de préparation de chlorhydrate de cinacalcet
US8575393B2 (en) 2009-03-05 2013-11-05 Cipla Limited Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process
WO2010103531A2 (fr) 2009-03-09 2010-09-16 Megafine Pharma (P) Ltd. Nouveau procédé pour la préparation de cinacalcet et nouveaux intermédiaires de cette préparation
WO2010104882A1 (fr) 2009-03-10 2010-09-16 Amgen Inc. Procédés de modulation de la motilité des spermatozoïdes
WO2010103429A1 (fr) 2009-03-10 2010-09-16 Pfizer Inc. Dérivés de l'acide 1,1-(diméthyl-éthylamino)-2-hydroxy-propoxy]-éthyl}-3-méthyl-biphényl-4-carboxylique utiles en tant qu'antagonistes des récepteurs du calcium
RU2595720C2 (ru) * 2009-04-09 2016-08-27 Когнишн Терапьютикс, Инк. Ингибиторы снижения когнитивных способностей
WO2010128388A2 (fr) 2009-05-08 2010-11-11 Aurobindo Pharma Limited Procédé amélioré pour la préparation de composés intermédiaires utiles pour la préparation de cinacalcet
EP2435400A2 (fr) 2009-05-27 2012-04-04 Leo Pharma A/S Composés inédits modulant les récepteurs du calcium et leur utilisation pharmaceutique
US8765676B2 (en) 2009-05-27 2014-07-01 Leo Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (fr) * 2009-06-25 2010-12-29 第一三共株式会社 Dérivé de l'indoline
US9192585B2 (en) 2009-07-31 2015-11-24 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
CA2769659C (fr) 2009-09-10 2017-10-24 Zach System S.P.A. Procede de preparation de cinacalcet
WO2011033473A1 (fr) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Procédé pour la préparation de cinacalcet
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
AU2010315805B2 (en) 2009-09-29 2015-09-17 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
EP2486002B1 (fr) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Acétamides d'hétéroaryl- et aryl-cyclopropylamine substitués et leur utilisation
EP2314286A1 (fr) 2009-10-21 2011-04-27 Ratiopharm GmbH Cinacalcet en granulés à fondre
CN102119137A (zh) * 2009-11-02 2011-07-06 上海威智医药科技有限公司 盐酸西那卡塞的合成方法
IT1396623B1 (it) * 2009-11-26 2012-12-14 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet e suoi intermedi
WO2011106573A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase utilisés dans le traitement et la prévention de maladies et de troubles associés à hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
JP5968880B2 (ja) 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
US8946474B2 (en) 2010-06-30 2015-02-03 Leo Pharma A/S Polymorphic form of a calcimimetic compound
US8921606B2 (en) * 2010-07-16 2014-12-30 Hetero Research Foundation Process for cinacalcet hydrochloride
SI2598482T1 (sl) 2010-07-29 2018-09-28 Oryzon Genomics, S.A. Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba
WO2012013727A1 (fr) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
WO2012045883A1 (fr) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Inhibiteurs d'oxydases de cyclopropylamine
CN101993379B (zh) * 2010-10-22 2013-06-19 能特科技股份有限公司 一种盐酸西那卡塞的制备方法
RU2013128968A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительного рецептора
US20130244995A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
EP2643298A1 (fr) 2010-11-26 2013-10-02 Leo Pharma A/S Cyclopentylazines substituées en tant que composés casr-actifs
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
CA3140885A1 (fr) 2010-12-13 2012-06-21 Quiapeg Pharmaceuticals Ab Polymeres fonctionnalises
WO2012107498A1 (fr) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Inhibiteurs de lysine diméthylase pour des troubles myéloprolifératifs
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
RS58475B1 (sr) 2011-10-20 2019-04-30 Oryzon Genomics Sa Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori
CZ303627B6 (cs) 2011-11-25 2013-01-16 Zentiva, K.S. Zpusob výroby Cinacalcetu
CN103450027B (zh) 2012-05-29 2015-07-29 上海京新生物医药有限公司 盐酸西那卡塞的制备方法
CA2876315C (fr) 2012-06-12 2021-05-25 Marek Kwiatkowski Conjugues de molecules biologiquement actives a des polymeres fonctionnalises
US20150344407A1 (en) * 2012-08-21 2015-12-03 The Board Of Regents Of The University Of Texas System Fendiline derivatives and methods of use thereof
WO2014033604A1 (fr) * 2012-08-27 2014-03-06 Lupin Limited Composés d'arylalkylamine jouant le rôle de modulateurs des récepteurs sensibles au calcium
FR2995307A1 (fr) 2012-09-07 2014-03-14 Prod Chim Auxiliaires Et De Synthese Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables
PL2730279T3 (pl) 2012-11-09 2015-12-31 K H S Pharma Holding Gmbh Preparaty cynakalcetu o natychmiastowym uwalnianiu
WO2014096277A1 (fr) 2012-12-21 2014-06-26 Synthon B.V. Composition de comprimé comprenant du chlorhydrate de cinacalcet
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10016374B2 (en) 2013-06-26 2018-07-10 Jubilant Generics Limited Disintegrant free composition of Cinacalcet
AU2015210852B2 (en) 2014-01-31 2019-01-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
CN104045568A (zh) * 2014-06-18 2014-09-17 中山奕安泰医药科技有限公司 一种合成(r)-1–(萘-1-基)乙胺的新工艺
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104478736B (zh) * 2014-12-16 2016-07-13 成都启泰医药技术有限公司 一种盐酸西那卡塞的制备方法
WO2016193882A1 (fr) 2015-05-29 2016-12-08 Lupin Limited Procédé de préparation d'un intermédiaire de cinacalcet et chlorhydrate de cinacalcet
EP4596045A3 (fr) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Procédés de traitement de la vitamine d
AU2018231832A1 (en) 2017-03-10 2019-08-08 Quiapeg Pharmaceuticals Ab Releasable conjugates
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
EP3849660A1 (fr) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Conjugués de glp-1 libérables
CN111196759B (zh) * 2018-11-16 2023-03-24 上海博志研新药物技术有限公司 盐酸西那卡塞及其中间体的制备方法
MX2022002282A (es) * 2019-08-28 2022-03-25 Unilever Ip Holdings B V Compuestos novedosos para aclarar la piel.
EP4125840A1 (fr) 2020-03-27 2023-02-08 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement de synucléinopathies
RU2739376C1 (ru) * 2020-07-24 2020-12-23 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) Способ получения фендилина

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2276618A (en) 1942-03-17 N-phenylaliphatic bihxdroxithenyl-
US2930731A (en) 1952-04-08 1960-03-29 Upjohn Co Bis[beta-(ortho-hydrocarbonoxyphenyl)iso-propyl]amines
BE570596A (fr) 1957-08-26
BE621300A (fr) 1961-08-14
US3262977A (en) 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
NL293886A (fr) 1962-06-19 1965-04-12 Merck Ag E
US3318952A (en) 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3459767A (en) 1965-08-10 1969-08-05 Pfizer & Co C Aminomethylindoles
GB1109924A (en) 1965-11-29 1968-04-18 Roche Products Ltd Novel substituted diphenylalkyl amines and a process for the manufacture thereof
DE1618005A1 (de) 1966-09-22 1971-09-09 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen
CH480791A (de) 1967-01-17 1969-11-15 Ciba Geigy Schädlingsbekämpfungsmittel
GB1263987A (en) 1969-05-30 1972-02-16 Allen & Hanburys Ltd Phenethylamine derivatives
US4129598A (en) * 1972-05-31 1978-12-12 Synthelabo Phenylethylamine derivatives
GB1448437A (en) 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US3862925A (en) 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US4000197A (en) * 1973-07-23 1976-12-28 The University Of Iowa Research Foundation Asymmetric synthesis of phenylisopropylamines
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (fr) 1974-03-08 1982-06-04
US4014937A (en) 1974-08-26 1977-03-29 Pfizer Inc. 3,4-And 3,5-dialkoxyphenethylamines
HU169507B (fr) 1974-09-25 1976-12-28
US3987201A (en) 1974-12-24 1976-10-19 Eli Lilly And Company Method for treating arrhythmia
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
JPS5390272A (en) 1977-01-13 1978-08-08 Sendai Fukusokan Kagaku Kenkiy Method of producing optically active salsolizine
US4608391A (en) 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
US4289787A (en) 1977-12-19 1981-09-15 Eli Lilly And Company Quaternary ammonium antiarrhythmic drugs
DD144050A5 (de) 1978-06-05 1980-09-24 Ciba Geigy Ag Verfahren zur herstellung von n-alkylierten aminoalkoholen
DE2825961A1 (de) 1978-06-14 1980-01-03 Basf Ag Fungizide amine
CA1145767A (fr) 1978-07-03 1983-05-03 Jack Mills Phenethanolamines, composes les contenant et methode pour maigrir
US4391826A (en) 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
ZA794872B (en) 1978-09-20 1980-11-26 Schering Corp A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it
FR2436773A1 (fr) 1978-09-22 1980-04-18 Roussel Uclaf Nouveaux derives du 3-(aminoethyl) phenol et leurs sels, procede de preparation et application a titre de medicaments
DE2841184C2 (de) * 1978-09-22 1986-09-25 Hochtemperatur-Reaktorbau GmbH, 4600 Dortmund Vorrichtung zur Durchmischung der Heißgassträhnen bei einem gasgekühlten Hochtemperaturreaktor
US4360511A (en) 1978-11-29 1982-11-23 Medi-Physics, Inc. Amines useful as brain imaging agents
DD150456A5 (de) 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
DE3061334D1 (en) 1979-06-16 1983-01-20 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
JPS603387B2 (ja) 1980-07-10 1985-01-28 住友化学工業株式会社 新規光学活性イミダゾリジン−２−オン誘導体およびその製法
HU183430B (en) 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
US4591605A (en) 1981-11-10 1986-05-27 Research Foundation Of State University Of New York Method and ingestible formulation for inhibiting the secretion of stomach acid
US4658060A (en) 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
DE3225879A1 (de) 1982-07-10 1984-01-12 Basf Ag, 6700 Ludwigshafen Trans-3-(4'-tert.-butylcyclohexyl-1')-2-methyl-1-dialkyl-aminopropane, ihre herstellung und verwendung als arzneimittel
CA1258454A (fr) 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
US4647446A (en) 1982-08-18 1987-03-03 The Regents Of The University Of California Rapid brain scanning radiopharmaceutical
JPS5950358A (ja) 1982-09-14 1984-03-23 Sumitomo Chem Co Ltd 光学活性なカルボン酸をグラフトしたクロマトグラフ充填剤およびそれを用いる鏡像体混合物の分離法
US4677101A (en) 1983-09-26 1987-06-30 Merck & Co., Inc. Substituted dihydroazepines useful as calcium channel blockers
US4661635A (en) 1983-11-21 1987-04-28 Mcneilab, Inc. Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives
US5334628A (en) 1984-06-09 1994-08-02 Kaken Pharmaceutical Co., Ltd. Amine derivatives, processes for preparing the same and fungicides containing the same
US4587253A (en) 1984-07-30 1986-05-06 Merck & Co., Inc. Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4609494A (en) 1985-02-21 1986-09-02 Merck & Co., Inc. 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers
US4839369A (en) 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8522186D0 (en) 1985-09-06 1985-10-09 Erba Farmitalia Cycloalkyl-substituted 4-aminophenyl derivatives
DE3541181A1 (de) 1985-11-21 1987-05-27 Basf Ag Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US4675321A (en) 1986-02-07 1987-06-23 Merck & Co., Inc. Substituted pyrimidines useful as calcium channel blockers
US5034514A (en) 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
US5030576A (en) 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4808718A (en) 1986-05-06 1989-02-28 Merck & Co., Inc. Fused polycyclic and bridged compounds useful as calcium channel blockers
HU200591B (en) 1986-07-11 1990-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
IL83163A (en) 1986-07-18 1991-06-10 Erba Carlo Spa Cycloalkyl-substituted 4-pyridyl derivatives,their preparation and pharmaceutical compositions containing them
HU207280B (en) 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
US5064657A (en) 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US4925664A (en) 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
EP0270376B1 (fr) 1986-12-04 1992-09-30 Asahi Kasei Kogyo Kabushiki Kaisha Dérivés peptidiques liés au gène de la calcitonine
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US4916145A (en) 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
ATE128359T1 (de) 1988-01-11 1995-10-15 Amylin Pharmaceuticals Inc Behandlung von diabetes mellitus typ 2.
US5001251A (en) 1988-01-15 1991-03-19 E. R. Squibb & Sons, Inc. Optical resolution of DL-3-acylthio-2-methylpropanoic acid
FI904827A7 (fi) 1988-04-04 1990-10-01 The Salk Inst Biotechnology/ Kalsiumkanavakoostumuksia ja -menetelmiä
US5082837A (en) 1988-06-28 1992-01-21 Merrell Dow Pharmaceuticals Lactamimides as calcium antagonists
US4925873A (en) 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists
JPH02200658A (ja) 1989-01-28 1990-08-08 Kumiai Chem Ind Co Ltd Ｎ―（置換）ベンジルカルボン酸アミド誘導体及び除草剤
RU2005717C1 (ru) * 1989-02-17 1994-01-15 Такеда кемикал-индастриз Лтд Способ получения производных аралкиламинов или их кислотно-аддитивных солей
US5011834A (en) 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
DD298412A5 (de) 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
IL94963A0 (en) 1989-07-03 1991-06-10 Univ New York Use of polyamines as ionic-channel regulating agents
GB8915712D0 (en) 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
US5021599A (en) 1989-08-31 1991-06-04 Serpentix Conveyor Corporation Redox-responsive anion receptors
US5053337A (en) 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
US5096908A (en) 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
WO1992007829A1 (fr) 1990-11-02 1992-05-14 The Upjohn Company Indole-3-methanamines utilisees en tant qu'agents antidiabetiques, antiobesite et antiatherosclerotiques
DE69233479T2 (de) 1991-02-08 2006-03-16 Scion Pharmaceuticals, Inc., Medford Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
DK0508307T3 (da) 1991-04-08 1995-12-27 Sumitomo Chemical Co Optisk aktive sekundære aminforbindelser, fremgangsmåde til fremstilling af en optisk aktiv sekundær aminforbindelse og fremgangsmåde til fremstilling af en optisk aktiv carboxylsyre ved anvendelse af denne forbindelse
US5688938A (en) 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
DK0724561T3 (da) * 1991-08-23 2004-06-28 Nps Pharma Inc Calciumreceptoraktive arylalkylaminer
US5763569A (en) 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
ES2256370T3 (es) 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
FI942187A7 (fi) 1991-11-12 1994-05-11 Pfizer Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
JPH07502524A (ja) 1991-12-30 1995-03-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ α−置換ベンゼンメタナミン誘導体
WO1993015044A1 (fr) 1992-01-29 1993-08-05 Smithkline Beecham Corporation Derives d'acide n-benzyloxamique, d'oxamate et d'oxamide et leur utilisation comme inhibiteurs du facteur de necrose tumorale (fnt) et de la phosphodiesterase iv (pde iv)
JP3175339B2 (ja) * 1992-10-07 2001-06-11 住友化学工業株式会社 光学活性アミン化合物、その製法、その中間体及びその用途
EP0637237B1 (fr) * 1993-02-23 2004-05-19 Brigham And Women's Hospital, Inc. Molecules actives sur les recepteurs du calcium
GB9326403D0 (en) 1993-12-24 1994-02-23 Oxford Asymmetry Ltd Improvements in or relating to chiral syntheses
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase
EP1203761B1 (fr) * 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Composés capables de moduler l'activité du récepteur de calcium
US7043457B1 (en) 2000-06-28 2006-05-09 Probuild, Inc. System and method for managing and evaluating network commodities purchasing
US20060283332A1 (en) 2001-12-11 2006-12-21 Garman Michael H Hot beverage maker
US8526300B2 (en) 2008-03-31 2013-09-03 Ericsson Ab Method and apparatus for providing resiliency in multicast networks
KR101411428B1 (ko) 2012-07-12 2014-06-24 한국과학기술원 집광식 휴대용 형광 검출 시스템

Also Published As

Publication number Publication date
JP2882882B2 (ja) 1999-04-12
HU229474B1 (en) 2014-01-28
PL319812A1 (en) 1997-09-01
JPH11130737A (ja) 1999-05-18
WO1996012697A3 (fr) 1996-06-13
NL300199I1 (nl) 2005-08-01
ES2234768T3 (es) 2005-07-01
US6211244B1 (en) 2001-04-03
JP4002338B2 (ja) 2007-10-31
CZ290670B6 (cs) 2002-09-11
TW200402407A (en) 2004-02-16
FR05C0029I1 (fr) 2005-08-12
DE69533948D1 (de) 2005-02-24
EP1203761A2 (fr) 2002-05-08
DE122005000033I2 (de) 2006-11-23
ATE359259T1 (de) 2007-05-15
CZ118297A3 (en) 1997-09-17
CA2202879A1 (fr) 1996-05-02
CA2202879C (fr) 2005-08-30
HU0700718D0 (en) 2008-12-29
DE69535461D1 (de) 2007-05-24
AU709303B2 (en) 1999-08-26
HK1052685A1 (en) 2003-09-26
PT1203761E (pt) 2005-04-29
BRPI9509411B1 (pt) 2016-12-06
DE69533948T2 (de) 2005-12-15
KR100293621B1 (ko) 2001-11-26
HK1046900B (en) 2005-07-29
AU4195796A (en) 1996-05-15
LU91182I9 (fr) 2019-01-07
CN1312116C (zh) 2007-04-25
DE69535461T2 (de) 2008-09-25
CN1534016A (zh) 2004-10-06
NZ297157A (en) 1999-08-30
HK1046900A1 (en) 2003-01-30
LU91182I2 (fr) 2006-07-11
BRPI9509411A (pt) 1997-12-30
UA55374C2 (uk) 2003-04-15
CZ292709B6 (cs) 2003-11-12
EP0787122A2 (fr) 1997-08-06
EP1203761A3 (fr) 2002-05-15
RU2195446C2 (ru) 2002-12-27
WO1996012697A2 (fr) 1996-05-02
EP0787122B1 (fr) 2007-04-11
JPH10513436A (ja) 1998-12-22
JP4353985B2 (ja) 2009-10-28
TW568896B (en) 2004-01-01
EP1553078A1 (fr) 2005-07-13
CN1220658A (zh) 1999-06-23
NL300199I2 (nl) 2005-10-03
JP2007204482A (ja) 2007-08-16
DE122005000033I1 (de) 2005-09-29
EP1275635A1 (fr) 2003-01-15
ATE287390T1 (de) 2005-02-15
HUT77980A (hu) 1999-02-01
HK1020041A1 (en) 2000-03-10
WO1996012697A9 (fr) 2000-08-24
HK1002454A1 (en) 1998-08-28
CN1147459C (zh) 2004-04-28
BRPI9509411B8 (pt) 2021-07-06
EP1203761B1 (fr) 2005-01-19
PL183499B1 (pl) 2002-06-28
ES2285707T3 (es) 2007-11-16
FR05C0029I2 (fr) 2006-12-29
HU228150B1 (en) 2012-12-28
EP0787122B9 (fr) 2007-10-17
KR100403094B1 (ko) 2003-11-13

Similar Documents

Publication Publication Date Title
NL300199I2 (nl) Calcium-receptor actieve verbindingen.
DE69216501D1 (de) Turbinenschaufel mit Innenkühlungskanal
DE3683175D1 (de) Azolylmethyloxirane - ihre herstellung und verwendung als pflanzenschutzmittel.
ES2110421T3 (es) O-bencil-oximeteres y los agentes protectores de las plantas que contienen estos compuestos.
SE8402188D0 (sv) Fenetanolaminderivat
FI924709A7 (fi) På hartsemulsion baserat ytlimningsmedel, ett därmed limmat papper och ett limningsförfarande för utnyttjande därav
DE69923914D1 (de) Strömungsmaschinenschaufel mit aparter Kühlung der Anströmkante
FI935091A0 (fi) Foerfarande och anordning foer kanalbegaeran i ett kommunikationssystem
FI905035A7 (fi) Anordning för feldetektering och bandbreddsövervakning avsedd för användning i ett paketkopplat arrangemang
FI925330A0 (fi) Substituerade fenylfenoler som leukotrienantagonister
DE60102161D1 (de) Cumarin-derivate mit comt hemmender wirkung
BR9205996A (pt) Guilhotina rotativa e tangencial para lâminas
FI925834L (fi) Foerfarande och anordning, med vilket utfoeres ett arbetsskede med ett mekaniskt verktyg
FI930852A0 (fi) Foerledning foer bildande av ett roekgas ledande skorstensinnefoer av en husskorsten som behoever sanering, foerfarande foer framstaellning av en roerledning och anvaendning av densamma
FI934830A0 (fi) Foerfarande och anordning foer differentiell modulation av signaler i ett flerkanals-oeverfoeringssystem
NO306618B1 (no) Farnesyloeproteintransferaseinhibitorer som anticancermidler
DE69314716D1 (de) Kreissägeblatt
FI921408L (fi) Foerfarande foer skjutning av en borrstaong in i ett utslagshaol av en schaktugn, borrmaskin och duppelriktad klaemma
FI905651A7 (fi) Energi och kylmaskineri sparande kylanordning.
BE797911A (fr) Pyrrolidylideneurees, piperidylideneurees et hexahydroazepinylidenfurees
FI915981L (fi) Tejpupplindningspultrusionsprocess foer framstaellning profiler av foerstaerkningsplast och foerstaerkningsplastprofil som framstaellts med foerfarandet
FIU930448U0 (fi) Maetapparat foer effekt och energi som oeverfoerts av ett elastiskt effekttransmissionsorgan saosom kedja, lina, vajer eller olika remmar
BR9102909A (pt) Refrigerador para chopp
FI911240A0 (fi) Faestningsyta foer ett gasmunsstycke i en svetsningsbraennare och foerfarande foer tillverkning daerav.
KR950017204U (ko) 톱밥제조기의 톱날 설치구조